An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the long-term safety and tolerability of human
corticotropin-releasing factor (hCRF), XERECEPT®, in patients requiring dexamethasone
(Decadron) to treat peritumoral brain edema. This open-label, extended-use study is open to
all patients who participate in either of the blinded studies, NTI 0302, NTI 0303, or other
designated studies, including patients who may have discontinued blinded study medication
early but completed the protocol-stipulated follow-up periods.